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Mid1 and Mid2 are ubiquitin ligases that regulate
microtubule dynamics and whose mutation is asso-
ciated with X-linked developmental disorders. We
show that astrin, a microtubule-organizing protein,
co-purifies with Mid1 and Mid2, has an overlapping
localizationwithMid1 andMid2 at intercellular bridge
microtubules, is ubiquitinated by Mid2 on lysine 409,
and is degraded during cytokinesis. Mid2 depletion
led to astrin stabilization during cytokinesis, cytoki-
netic defects, multinucleated cells, and cell death.
Similarly, expression of a K409A mutant astrin in
astrin-depleted cells led to the accumulation of
K409A on intercellular bridgemicrotubules and an in-
crease in cytokinetic defects, multinucleated cells,
and cell death. These results indicate that Mid2 reg-
ulates cell division through the ubiquitination of as-
trin on K409, which is critical for its degradation
and proper cytokinesis. These results could help
explain how mutation ofMID2 leads to misregulation
ofmicrotubule organization and the downstreamdis-
ease pathology associated with X-linked intellectual
disabilities.
INTRODUCTION
The TRIM/RBCC (tripartite motif composed of a RING finger,
zinc binding motif/s called B-box/s, and a coiled coil region)
superfamily of E3 ubiquitin ligases has variable roles in cellular
homeostasis, including signaling, regulation of cytoskeletal
structures, and cell-cycle progression (Meroni and Diez-Roux,
2005). The Mid1 (midline 1, or Trim18) and Mid2 (midline 2, or
Trim1) ubiquitin ligases belong to the C-I TRIM subfamily and
share a similar domain architecture, with an N-terminal tripartite
motif and FN3 (fibronectin type III) and B30.2-like/RFP (Ret finger180 Cell Reports 14, 180–188, January 12, 2016 ª2016 The Authorsprotein) domains at their C terminus (Meroni and Diez-Roux,
2005; Figure 1A). Mid1 and Mid2 also contain a COS (C-terminal
subgroup one signature) box between the coiled coil and FN3
motif that mediates the binding of these proteins to microtubules
(Short and Cox, 2006; Figure 1A).
Mid1 and Mid2 have critical roles during development, and
mutation of MID1 has been linked to Opitz syndrome (MIM:
300000), an X-linked disease characterized by congenital anom-
alies that is manifested by the abnormal closure of midline struc-
tures (Cainarca et al., 1999), whereas mutation ofMID2 has been
linked to X-linked intellectual disabilities (MIM: 300204; Geetha
et al., 2014).Mid1 andMid2 homo- and heterodimerize (Cainarca
et al., 1999; Short et al., 2002) and have been implicated in
anchoring proteins to microtubules, in the bundling and stabiliz-
ing of microtubules, and in organizingmicrotubules during neural
tube closure (Berti et al., 2004; Short et al., 2002; Suzuki et al.,
2010). Therefore, Mid1 and Mid2 have roles in microtubule sta-
bility and organization; however, whether their ubiquitin ligase
activities are required for regulating these processes remains
to be determined. Although Mid1 ubiquitination substrates
include alpha4, the catalytic subunit of protein phosphatase
2A, and Fu, whether ubiquitination of these proteins leads to
changes in microtubule organization has not been explored
(Du et al., 2013; Schweiger et al., 2014; Trockenbacher et al.,
2001). Additionally, to our knowledge, there are no known sub-
strates of Mid2 that can explain its role in regulating microtubule
organization.
To better understand the molecular basis of X-linked develop-
mental diseases associated withmutation ofMID1 andMID2, we
analyzed the Mid1 and Mid2 interactomes and identified SPAG5
(sperm-associated antigen 5, aka hMAP126 and astrin). Astrin is
a microtubule-bundling/organizing protein critical for regulating
microtubules during cell division (Gruber et al., 2002; Mack
and Compton, 2001; Thein et al., 2007). Mid1 and Mid2 showed
an overlapping localization with astrin to intercellular bridge mi-
crotubules (ICBMTs). Depletion of Mid1 or Mid2 arrested cells
during cytokinesis and generated binucleated cells. Importantly,
Mid2 ubiquitinated astrin on lysine 409 during mitotic exit and
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Figure 1. Astrin Associates with Mid1
and Mid2
(A) Mid1, Mid2, and astrin domain architecture with
the number of amino acids indicated. B, B-box;
B30.2L = B30.2-like/RFP (Ret finger protein motif);
CC, coiled coil; CC1/2 = coiled coil 1/2; cos =
C-terminal subgroup one signature box; FN3,
fibronectin type III; R, RING finger.
(B) Silver-stained gels of control (LAP only), LAP-
Mid1, and LAP-Mid2 tandem affinity purifications.
E, eluates; HSS, high spin supernatant; MW, mo-
lecular weight. Protein bands corresponding to
Mid1, Mid2, astrin, tubulin, and proteasome sub-
units are indicated. The ten gel slices analyzed by
LC-MS/MS are indicated with red lines.
(C) Mid1 (red) and Mid2 (blue) interactomes visu-
alized with Cytoscape showing the four major
categories of interacting proteins: tubulin isoforms;
proteasome subunits; centrosome proteins; and
astrin. For details, see Table S1.
(D) Summary of mass spectrometry data showing
the top Mid1 and Mid2 interactors including pro-
tein name, number of peptides identified, number
of unique peptides, and the percent protein
coverage.
(E) IPs from HEK293 cell extracts using anti-astrin
or control IgG antibodies were immunoblotted with
the indicated antibodies. Note that Mid1 and Mid2
coIP with endogenous astrin.
(F and G) Anti-GFP antibodies were used to
perform IPs from LAP-Mid1 (F) or LAP-Mid2 (G) cell
extracts prepared from thymidine- or nocodazole-
arrested cells in the presence of nocodazole. IPs
were immunoblotted with the indicated antibodies.
Note that Mid2 and astrin coIP with LAP-Mid1 (F)
and Mid1 and astrin coIP with LAP-Mid2 (G).
(H) In vitro IPs with S-35-radiolabeled HA-tagged
astrin (full-length and indicated fragments) or
luciferase and FLAG-tagged Mid1 or Mid2. Note
that astrin (full-length and 1-481) coIPs with both
Mid1 and Mid2. See also Figure S1.was required for astrin degradation. Experiments where endog-
enous astrin was depleted and wild-type or a K409A (Mid2 ubiq-
uitination-resistant mutant) astrin were reintroduced showed
that astrin-K409A accumulated at ICBMTs, arrested cells during
cytokinesis, and led to an increase in binucleated cells and cell
death. These data indicate that Mid2 ubiquitinates and targets
a pool of astrin for degradation during cytokinesis, which is
important for proper cytokinesis.
RESULTS
Mid1 and Mid2 Associate with Astrin
To understand the molecular basis of X-linked developmental
disorders associated with mutation of MID1 and MID2, we
began by defining the Mid1- and Mid2-interacting proteins.
HEK293 doxycycline-inducible localization and affinity purifica-
tion (LAP = EGFP-TEV-S-peptide)-tagged Mid1 and Mid2 stableCcell lines were used to express and tandem affinity purify LAP-
Mid1/Mid2 (Torres et al., 2009). Eluates were resolved by SDS-
PAGE, and ten gel slices were excised and analyzed individually
by mass spectrometry (Figure 1B). Cytoscape data analysis
showed that Mid1 and Mid2 associated with each other, as re-
ported previously (Short et al., 2002), and with proteasome sub-
units, tubulin and astrin, whereas Mid2 also associated with the
centrosomal proteins ASPM and Cep128 (Figures 1C and 1D;
Table S1). Due to astrin’s role in crosslinking/bundling microtu-
bules and its identification in Mid1 and Mid2 purifications, we
sought to validate these interactions. First, endogenous astrin
was immunoprecipitated (IPed) with anti-astrin antibodies and
immunoblot analysis of the IPs showed that Mid1 and Mid2
co-immunoprecipitated (coIPed) with astrin (Figure 1E). Next,
LAP-Mid1 or Mid2 were IPed from G1/S or G2/M extracts in
the presence of nocodazole (microtubule depolymerizer) and as-
trin coIPed with both Mid1 and Mid2 under both conditions,ell Reports 14, 180–188, January 12, 2016 ª2016 The Authors 181
Figure 2. The Localization of Mid1, Mid2, and Astrin Overlaps at ICBMTs
Immunofluorescence microscopy of LAP-Mid1- or Mid2-expressing cells stained for DNA, a-tubulin, and Plk1 (A and B), TPX2 (C and D), or astrin (E and F). Note
that Mid1 andMid2 localize to ICBMTs overlapping with TPX2 and astrin and adjacent to the Plk1midbody staining. The scale bar represents 5 mm. Lower panels
show zoom images of the cytokinetic bridge region. The scale bar represents 2 mm.indicating that these interactions were not mediated by microtu-
bules andwere independent of the cell cycle (Figures 1F and 1G).
Consistently, nocodazole-treated in vitro binding experiments
showed that HA-tagged astrin full-length and a N-terminal frag-
ment (amino acids [aas] 1–481) coIPed with FLAG-tagged Mid1
andMid2, whereas themiddle region (aas 482–850) andC-termi-
nal region (aas 851–1,193) of astrin did not interact with Mid1 or
Mid2 (Figures 1H and S1). These results indicated that the N ter-
minus of astrin was interacting directly with Mid1 and Mid2.
Mid1, Mid2, and Astrin Localize to ICBMTs
Astrin localizes to spindle microtubules during mitosis and
ICBMTs during cytokinesis (Mack and Compton, 2001). Thus,
we asked whether Mid1 or Mid2 localized to ICBMTs like astrin.
LAP-Mid1- or Mid2-expressing cells were fixed and stained for
DNA, a-tubulin, and Plk1 or TPX2 or astrin. In cytokinetic cells,182 Cell Reports 14, 180–188, January 12, 2016 ª2016 The AuthorsLAP-Mid1 and Mid2 localized to ICBMTs partially overlapping
with TPX2 and astrin and adjacent to Plk1 staining at the mid-
body (Figures 2A–2F). These data indicated that the Mid1 and
Mid2 localization partially overlapped with astrin at ICBMTs dur-
ing cytokinesis.
Mid1 and Mid2 Are Required for Cell Division
Next, we asked whether Mid1 or Mid2 had a role in cell division.
HeLa cells were transfected with control (siCont) or MID1
(siMID1)- or MID2 (siMID2)-targeting siRNAs for 48 hr, fixed,
and stained for DNA and a-tubulin (Figures 3A and 3B). siMID1
and siMID2 cells showed a small increase in the percentage of
mitotic cells with defective spindles (multipolar and unfocused;
siMID1 = 14.7 ± 0.9, p < 0.05 and siMID2 = 15 ± 2.8, p < 0.05
compared to siCont = 9 ± 2.2) and mitotic cells with unaligned
chromosomes (where all but a few [one to three] chromosomes
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Figure 3. Depletion of Mid1 or Mid2 Leads to Cytokinetic Defects
(A) Immunoblot analysis showing that siRNA oligonucleotides targeting MID1 (siMID1) or MID2 (siMID2) deplete Mid1 or Mid2 compared to control non-targeting
siRNAs (siCont).
(legend continued on next page)
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were aligned at themetaphase plate; siMID1 = 9.3 ± 2.5, p < 0.05
and siMID2 = 19.7 ± 1.3, p < 0.0001 compared to siCont = 3.3 ±
1.3; Figures 3B–3D). siMID1 and siMID2 cells also showed a pro-
nounced increase in the percentage of cells undergoing cytoki-
nesis (siMID1 = 21.7 ± 2.9, p < 0.05 and siMID2 = 32.7 ± 3.4,
p < 0.001 compared to siCont = 12.0 ± 2.0) and interphase cells
with greater than one nuclei (siMID1 = 29.3 ± 3.7, p < 0.001 and
siMID2 = 33 ± 3.9, p < 0.001 compared to siCont = 7.3 ± 1.9; Fig-
ures 3B, 3E, and 3F). These results indicated that depletion of
Mid1 or Mid2 led to minor defects in early mitosis and major de-
fects in cytokinesis. Consistently, live-cell time-lapse micro-
scopy showed that siMID1 and siMID2 cells exhibited cell
division defects, including cytokinetic arrest with the two cells
linked by a cytokinetic bridge, a failure to divide with regression
into one binucleated cell, and cell division followed by death of
one or both cells (Figures 3G and 3H; Movies S1, S2, and S3).
siMID1 and siMID2 cells were also slower at completing abscis-
sion from the time of mitotic entry (siMID1 = 4.9 ± 0.76 hr,
p < 0.05 and siMID2 = 6.6 ± 0.87 hr, p < 0.05 compared to
siCont = 3.1 ± 0.36 hr; Figure 3I). Next, we asked whether siMID1
and siMID2 cytokinetic defects were due to ultra-fine DNA
bridges (UFBs) that go undetected by standard DNA staining
(Chan et al., 2007). However, no significant increase in UFBs
(visualized by staining for the BLM or PICH proteins) was seen
in siMID1 or siMID2 post-metaphase cells, indicating that their
cytokinetic defects were not due to UFBs (Figure S2). Together,
these data indicated that depletion of Mid1 or Mid2 led to a fail-
ure to undergo proper cytokinesis, the generation of binucleated
cells, and cell death.
Mid2 Regulates Astrin Protein Levels
Astrin levels were reported to increase as cells entered mitosis
and decrease as cells exit mitosis (Dunsch et al., 2011). Thus,
it was possible that Mid1 and Mid2 were associating with astrin
to regulate astrin levels through ubiquitination and proteasome-
dependent degradation. To test this, we first verified that astrin
levels decreased during mitotic exit. G2/M-arrested HeLa cells
were released, and protein samples were prepared at various
time points and analyzed by immunoblotting. In contrast to a pre-
vious study that showed two astrin bands (Dunsch et al., 2011),
using 4%–20% gradient gels, we were able to detect a third
slower mobility band (Figure S3A). This third band was present
in mitosis and disappeared as the cells exited mitosis concomi-
tant with a decrease in overall astrin levels (Figures 4A, 4B, S3B,(B) Immunofluorescence microscopy of HeLa cells treated with siCont, siMID1,
siMID2 cells have unaligned chromosomes, arrest during cytokinesis, and an inc
(C) Quantification of the percentage of cells with defective spindles. Data represe
*p < 0.05.
(D) Same as in (C), except that the percentage of mitotic cells with unaligned chr
(E) Same as in (C), except that the percentage of cytokinetic cells was quantified
(F) Same as in (C), except that the percentage of cells with greater than one nuc
(G) Live-cell time-lapse microscopy snapshots of HeLa cells treated with siCont
cytokinetic arrest, cell death, and regression of dividing cells into binucleated ce
(H) The percentage of cells undergoing normal cell division, arresting during cyto
binucleated state were quantified for siCont-, siMID1-, or siMID2-treated cells.
counted for each.
(I) Quantification of the time between mitotic entry and cell abscission for siCon
independent experiments, 50 cells counted for each. *p < 0.05. See also Figure
184 Cell Reports 14, 180–188, January 12, 2016 ª2016 The Authorsand S3C, see arrows). Next, we asked whether astrin was ubiq-
uitinated during mitotic exit by IPing LAP-astrin from G2/M-
arrested and released cells and immunoblotting for K48 and
K63 ubiquitin linkages. This revealed that astrin was modified
with K48 and K63 ubiquitin linkages in early mitosis (0 hr time
point) and during cytokinesis (4 hr post release; Figure S3D).
Next, we asked whether Mid1 or Mid2 had a role in regulating
astrin levels during mitotic exit. siCont-, siMID1-, and siMID2-
treated cells were arrested in G2/M, released, and protein sam-
ples were prepared every hour for 10 hr as cells exited mitosis. In
siCont and siMID1 cells, the modified form of astrin and the over-
all astrin levels decreased as the cells exited mitosis, whereas in
siMID2 cells, astrin remained stabilized (Figures 4A and 4B, see
arrows). These results indicated thatMid2 had a role in regulating
astrin levels during mitotic exit.
Next, we asked whether astrin was a Mid1 or Mid2 substrate
using in vitro ubiquitination assays with S-35-radiolabeled astrin
and LAP-Mid1- or LAP-Mid2-expressing extracts. LAP-Mid2 ex-
tracts ubiquitinated astrin, whereas LAP-Mid1 extracts were un-
able to (Figure 4C), and combining LAP-Mid1 and LAP-Mid2
extracts did not increase astrin ubiquitination beyond that with
LAP-Mid2 extracts (Figure S3E). Additionally, deletion of the first
80 amino acids, which contain the RING domain required for
ubiquitination activity in RING domain E3 ligases, abolished
Mid2’s ability to ubiquitinate astrin (Figure 4D). Interestingly, a
mutant form of Mid2 where arginine 347 is mutated to glutamine
(R347Q), which is found in individuals with X-linked intellectual
disability, localized to ICBMTs but did so rather diffusely
compared to wild-type Mid2 (Figure S3F). Additionally, the
R347Qmutation did not inhibitMid2’s ability to bind to (Figure S1)
and ubiquitinate astrin (Figure 4D). To map the amino acid resi-
due/s that were ubiquitinated by Mid2, LAP-astrin purifications
from G1/S and mitotic exit (4 hr post-nocodazole release) cells
were analyzed bymass spectrometry. Lysine 409 (K409) of astrin
was found ubiquitinated in cells exiting from mitosis and not in
G1/S cells (Figure S3G). To determine whether K409 was ubiqui-
tinated by Mid2, we first tested the ability of Mid2 to ubiquitinate
full-length, N-terminal, middle, or C-terminal astrin fragments
(Figure S3H). Mid2 was only able to ubiquitinate full-length astrin
and the N-terminal fragment of astrin that contained K409 (Fig-
ure S3H). However, Mid2 was unable to ubiquitinate astrin (full-
length or N-terminal fragment) when K409 was mutated to
an alanine (K409A; Figure S3H). These results indicated that
Mid2 was ubiquitinating astrin at K409 during mitotic exit.or siMID2 for 48 hr and stained for DNA and a-tubulin. Note that siMID1 and
reased number of binucleated cells. The scale bar represents 5 mm.
nt average ± SD of three independent experiments, 100 cells counted for each.
omosomes was quantified. *p < 0.05 and ***p < 0.001.
. *p < 0.05 and **p < 0.001.
lei was quantified. **p < 0.001.
, siMID1, or siMID2. Representative cell division defects are shown, including
lls. Time is in minutes. See also Movies S1, S2, and S3.
kinesis, dying during cell division, and failing cytokinesis and regressing to a
Data represent the average ± SD of three independent experiments, 50 cells
t-, siMID1-, or siMID2-treated cells. Data represent the average ± SD of three
S2.
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Figure 4. Mid2 Regulates Astrin Levels in a Cell-Cycle-Dependent Manner
(A and B) Analysis of astrin levels during mitotic exit. HeLa cells treated with control siRNA (siControl) or siRNA targeting Mid1 (siMID1) or Mid2 (siMID2) were
arrested inG2/Mwith nocodazole, released, and harvested at the indicated time points. Protein extracts were then analyzed by immunoblotting with the indicated
antibodies. Note that, in siCont cells, Mid1 and Mid2 protein levels remain constant, whereas astrin levels decrease as cells exit mitosis. Also note that siMID2
cells stabilize astrin during mitotic exit. Immunoblots shown are representative data from one of three independent experiments. (B) Quantification of astrin levels
during mitotic exit from (A) is shown. Data represent the average ± SD of three independent experiments. See also Figure S3.
(C) In vitro ubiquitination assays were performed with or without S-35-radiolabeled recombinant HA-astrin or HA-luciferase (HA-Luc; negative control) and LAP-
Mid1- or LAP-Mid2-expressing extracts. Reactions were resolved by SDS-PAGE, transferred onto a PVDF membrane, and ubiquitination was monitored by
radiometric analyses. Note that a smear of higher molecular weight bands appears in the reaction with LAP-Mid2-expressing extracts, indicative of astrin
ubiquitination. See also Figure S3.
(legend continued on next page)
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Consistently, whereas LAP-astrin levels decreased during
mitotic exit, LAP-astrin-K409A remained stabilized and was
degraded less efficiently (Figures 4E and 4F). Additionally,
LAP-astrin-K409A was only weakly ubiquitinated during mitotic
exit (4 hr post-nocodazole release) compared to LAP-astrin (Fig-
ure 4G). These data indicated that Mid2 was ubiquitinating astrin
at K409 and targeting astrin for degradation during cytokinesis.
TheMid2Ubiquitination-Resistant Astrin-K409AMutant
Inhibits Cytokinesis
To further establish that Mid2 regulated cell division through
ubiquitination of astrin on K409, we analyzed the consequences
of expressing astrin-K409A on cell division. Overexpression of
either LAP-astrin or LAP-astrin-K409A led to cell division defects
(Figures S4A and S4B). Interestingly, cells depleted of endoge-
nous astrin (using anti-ASTRIN siRNAs; Figure S4C) that
expressed siRNA-resistant LAP-astrin underwent proper cytoki-
nesis, whereas those expressing siRNA-resistant LAP-astrin-
K409A arrested during cytokinesis (LAP-astrin = 22% ± 4.5%
compared to LAP-astrin-K409A = 42% ± 4.9%; p < 0.05; Figures
4H and 4I). LAP-astrin-K409A also spread to a larger area on
ICBMTs during cytokinesis (Figure 4H), and fluorescence inten-
sity measurements showed that LAP-astrin-K409A accumulated
at ICBMTs compared to LAP-astrin (LAP-astrin = 135.6 ± 46.1
[a.u.] compared to LAP-astrin-K409A = 386 ± 96.7 [a.u.];
p < 0.05; Figure 4J). LAP-astrin-K409A-expressing cells also
had an increased percentage of interphase cells with greater
than one nuclei (mostly binucleate) compared to LAP-astrin-
expressing cells (LAP-astrin = 15 ± 2.5 compared to LAP-astrin-
K409A = 30 ± 4.3; p < 0.05; Figure 4K) and an increased
percentage of dead cells (LAP-astrin = 12 ± 2.9 compared to
LAP-astrin-K409A = 23 ± 2.5; p < 0.05; Figure 4L). These data
indicated that, in astrin-depleted cells, expression of LAP-astrin
promoted cytokinesis, whereas LAP-astrin-K409A was stabi-
lized during cytokinesis at ICBMTs leading to cytokinetic arrest,
cytokinetic failure, the generation of binucleated cells, and an in-
crease in cell death. Interestingly, similar LAP-astrin and LAP-
astrin-K409A levels were observed during early mitosis in
siCont-, siMID1-, and siMID2-treated cells by immunofluores-
cence, indicating thatMid1 orMid2were not regulating the levels
of astrin in early mitosis (Figures S4D and S4E). However, LAP-(D) In vitro ubiquitination assays performed as in (C) with LAP-Mid2-WT or D80 (
(E and F) HeLa cells expressing LAP-astrin-WT or LAP-astrin-K409Awere arrested
Protein extracts were then analyzed by immunoblotting with the indicated antibo
astrin-K409A remains stabilized. Immunoblots shown are representative data fro
and LAP-astrin-K409A levels during mitotic exit from (E) is shown. Data represen
(G) HeLa cells expressing HA-astrin-WT or HA-astrin-K409A were released form
mitotic exit (4 hr post-release). Immunoprecipitates were immunoblottedwith anti-
robustly, whereas mutant HA-astrin-K409A was only minimally ubiquitinated. Se
(H) Endogenous astrin proteins levels were depleted with siRNA targeting astrin (s
then fixed and stained for microtubules (anti-a-tubulin antibodies) and LAP-astri
(I) Quantification of the percentage of cells arrested at cytokinesis. Data represe
each. *p < 0.05.
(J) Quantification of the total fluorescence intensity of LAP-astrin or LAP-astrin-K
dependent experiments, 50 cells counted for each. **p < 0.005. See also Figure
(K) Quantification of the percentage of interphase cells with greater than one n
experiments, 100 cells counted for each. *p < 0.05.
(L) Quantification of the percentage of cell death. Data represent the average ± S
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at ICBMTs (Figure S4F). Finally, we analyzed the interdepen-
dencies of Mid1, Mid2, and astrin for their localization to
ICBMTs. Each protein was able to localize to ICBMTs indepen-
dent of the others, indicating that they did not rely on each other
for their localization to ICBMTs (Figures S4E and S4G).
DISCUSSION
This study aimed to increase our understanding of the molecular
basis of X-linked developmental disorders associated with mu-
tation of the MID1 and MID2 ubiquitin ligases. We determined
that Mid1 and Mid2 bound directly to the N terminus of astrin
and their localization overlapped with astrin at ICBMTs during
cytokinesis. Further, astrin was ubiquitinated during cytokinesis
at K409 in a Mid2-dependent manner and this modification was
necessary to degrade a pool of astrin. Consistently, Mid2 deple-
tion led to the stabilization of astrin during cell division, cytoki-
netic arrest, the generation of binucleate cells that failed
cytokinesis, and cell death. Furthermore, expression of mutant
astrin-K409A led to its stabilization during cell division, its accu-
mulation at ICBMTs, cytokinetic defects, and cell death. These
data indicate that Mid2 promotes cell division through ubiquiti-
nation of astrin on K409. Finally, these data indicate that Mid2
may regulatemicrotubule organization through the ubiquitination
and destruction of astrin, which helps to explain howmutation of
MID2 can lead to the misregulation of microtubule organization
and the downstream disease pathology that is associated with
individuals with X-linked intellectual disabilities. Interestingly,
the Mid2 missense mutation R347Q that has been linked to
X-linked intellectual disabilities abolishes Mid2 microtubule
binding (Geetha et al., 2014), localized to ICBMTs, but did so
rather diffusely compared to wild-type Mid2 and was able to
bind to and ubiquitinate astrin in vitro. Therefore, the R347Q
mutation does not appear to interfere with Mid2 ubiquitination
activity or Mid2 substrate binding and instead interferes with
the ability of Mid2 to localize to its proper subcellular location,
where its activity is required.
Several questions remain regarding Mid1 and Mid2 and their
regulation of microtubules and cell division. First, Mid1 does
not appear to be regulating astrin levels and we were unable tofirst 80 amino acids deleted) or R347Q (point mutation)-expressing extracts.
in G2/Mwith nocodazole, released, and harvested at the indicated time points.
dies. Note that LAP-astrin-WT is degraded during mitotic exit, whereas LAP-
m one of three independent experiments. (F) Quantification of LAP-astrin-WT
t the average ± SD of three independent experiments.
nocodazole arrest, and HA-astrin was IPed with anti-HA antibodies during
K48 ubiquitin chain antibodies. Note that wild-typeHA-astrin was ubiquitinated
e also Figure S3.
iASTRIN), and LAP-astrin-WT or LAP-astrin-K409A were expressed. Cells were
n (anti-GFP antibodies). The scale bar represents 2 mm. See also Figure S4.
nt the average ± SD of three independent experiments, 100 cells counted for
409A at the cytokinetic bridge. Data represent the average ± SD of three in-
S4.
uclei was quantified. Data represent the average ± SD of three independent
D of three independent experiments, 100 cells counted for each. *p < 0.05.
identify Mid1-specific interactors that would explain its role in
cytokinesis; thus, it will be important to determine whether
Mid1 has a direct influence on a process that regulates cell divi-
sion or whether it has substrates that regulate cell division that
are as yet unidentified. Second, the Mid2 interactome also iden-
tified ASPM (abnormal spindle-like, microcephaly-associated)
and CEP128 (centromeric protein 128), which associate with
centrosomes, and ASPM has also been linked to the regulation
of spindle assembly and cytokinesis (Higgins et al., 2010; Jakob-
sen et al., 2011; Paramasivam et al., 2007); thus, these proteins
should be explored further as potential Mid2 substrates.
EXPERIMENTAL PROCEDURES
Cell Culture and Cell Cycle Synchronization
Cell line growth and siRNA treatments with Dharmacon control non-targeting
siRNA (D-001810-10), and siRNAs targeting MID1 (D-006537-1), MID2
(D-006938-03), and ASTRIN (J-006839-05-08) were used as described previ-
ously (Torres et al., 2010). For G1/S arrest and release experiments, cells were
arrested with 2 mM thymidine for 18 hr, washed three times with PBS and two
times with complete media, and released into fresh media. For G2/M arrest
and release experiments, cells were arrested with 330 nM nocodazole for
16 hr, washed three times with PBS and two times with complete media,
and released into fresh media.
Plasmids, Mutagenesis, and Generation of Stable Cell Lines
For full-length MID1/MID2/MID2-D80/MID2-R347Q/ASTRIN/ASTRIN-K409A/
LUCIFERASE or ASTRIN/ASTRIN-K409A truncation expression, their cDNA
was fused to the C terminus of either HA (pCS2-HA-DEST), EGFP (pGLAP1),
or FLAG (pCS2-FLAG-DEST) as described previously (Torres et al., 2011).
pGLAP1-MID1/MID2/ASTRIN/ASTRIN-K409Awere used to generate doxycy-
cline-inducible HEK293 or HeLa Flp-In T-REx LAP-MID1/MID2/ASTRIN/
ASTRIN-K409A stable cell lines that express the fusion protein from a single
genetic locus as described previously (Torres et al., 2009).
LAP Purifications, Identification of Mid1- and Mid2-Associated
Proteins by LC-MS/MS, and IPs
LAP purifications, the identification of Mid1- and Mid2-associated proteins
and the identification of ubiquitination sites on astrin by LC-MS/MS, and IPs
were as described previously (Torres et al., 2009). Briefly, LAP-Mid1 or LAP-
Mid2 cell lines were induced with 0.1 mg/ml Dox for 16 hr, and cells were
harvested and lysed. Cleared lysates were subjected to tandem affinity purifi-
cations by incubation with anti-GFP antibody beads, and bound eluates were
incubated with S protein agarose. Final eluates were resolved on a 4%–20%
SDS-PAG, and ten gel slices corresponding to the entire lane of the SDS-
PAG were excised and prepared for examination by mass spectrometry. For
mapping the astrin mitotic ubiquitination site, LAP-astrin was purified from
thymidine arrested or cells released from nocodazole for 4 hr and tandem
affinity purified as described above. Mass spectrometry analyses were per-
formed at the Harvard Mass Spectrometry and Proteomics Resource Labora-
tory by microcapillary reverse-phase HPLC nano-electrospray tandem mass
spectrometry (mLC/MS/MS) on a Thermo LTQ-Orbitrap mass spectrometer
as described in Vanderwerf et al. (2009) or at the UCLA Pasarow Mass Spec-
trometry Laboratory on a Thermo LTQ-Orbitrap XL as described in Patananan
et al. (2014). For details, see Supplemental Experimental Procedures.
Ubiquitination Reactions
Ubiquitination reactions were as described previously (Senese et al., 2015),
except that recombinant astrin was incubated with mitotic HEK293, LAP-
Mid1, or LAP-Mid2 cell extracts. For details, see Supplemental Experimental
Procedures.
Immunofluorescence and Live-Cell Time-Lapse Microscopy
Immunofluorescence microscopy was carried out as described previously
(Torres et al., 2010). HeLa or HEK293 stable cell lines were induced to expressCMid1 or Mid2 for 24 hr and fixed, permeabilized, and co-stained with the indi-
cated antibodies. Images were captured with a Leica DMI6000 microscope
(Leica DFC360 FX Camera; 633/1.40-0.60 NA oil objective; Leica AF6000
software). Images were deconvolved with Leica Application Suite 3D Decon-
volution software and exported as TIFF files. For quantifying spindle and cyto-
kinetic defects, 100 cells from three independent experiments were counted
and the data are presented as the average ± SD. For time-lapse microscopy,
HeLa cells were transfected with indicated siRNAs for 24 hr, arrested in G1/S
with 2 mM thymidine for 18 hr, washed, and released. Cells were imaged live
5 hr post-release for 20 hr using a Leica DMI6000 microscope, described
above, at 37C and 5% CO2 using a 203/0.4 NA air objective. Images were
converted to AVI movies. Each frame represents a 5-min interval. For details
and a list of antibodies used, see Supplemental Experimental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, one table, and six movies and can be found with this article online
at http://dx.doi.org/10.1016/j.celrep.2015.12.035.
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